<DOC>
	<DOCNO>NCT01984138</DOCNO>
	<brief_summary>This study investigate whether breast cancer patient experience vaginal dryness anti-estrogen treatment could benefit either vaginal estrogen vaginal moisturizer call Replens .</brief_summary>
	<brief_title>REVIVE : Replens Versus Intra-Vaginal Estrogen Treatment Vaginal Dryness Aromatase Inhibitor Therapy</brief_title>
	<detailed_description>To evaluate Estring versus Replens treatment atrophic vaginitis breast cancer survivor adjuvant aromatase inhibitor therapy . PRIMARY OBJECTIVE 1 . To compare improvement atrophic vaginitis sign symptom woman vaginal estrogen ring Replens vaginal cream . 1.1 Administer questionnaire baseline , 4 week , 12 week , 24 week patient assess vaginal dryness vaginal itching . Over six month , expect patient receive vaginal estrogen improvement atrophic vaginitis symptom compare woman Replens . SECONDARY OBJECTIVES 2.1 Assess compliance aromatase inhibitor ( AI ) therapy arm see whether vaginal estrogen therapy increase AI compliance among woman atrophic vaginitis . Compliance check count pill clinic visit 4 week , 12 week , 24 week study treatment period , every 6 month period 4.5 additional year , completion aromatase inhibitor therapy . We expect compliance vaginal estrogen arm superior Replens arm . Women age 18 diagnosed stage I-III ER+ breast cancer currently take adjuvant AI therapy also complain atrophic vaginitis symptom include vaginal dryness , vaginal itching , frequent urinary tract infection , dyspareunia candidate study . Women also must post-menopausal defined following : age &gt; 55 year , history bilateral oophorectomy , amenorrhea 1 year intact uterus ovary , serum estradiol FSH concentration post-menopausal range along either amenorrhea 6 month previous hysterectomy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Psyllium</mesh_term>
	<mesh_term>Calcium polycarbophil</mesh_term>
	<criteria>1. female 2. 18 year age old . 3. stage IIII ER+ breast cancer 4. postmenopausal define follow : age &gt; 55 year , history bilateral oophorectomy , amenorrhea 1 year intact uterus ovary , serum estradiol FSH concentration postmenopausal range along either amenorrhea 6 month previous hysterectomy . 5. currently take adjuvant AI therapy 6. vaginal dryness , dyspareunia , â‰¥3 urinary tract infection per year since start AI therapy 7 . Patients must agree use additional estrogen five year study period . However , use nonestrogen containing lubricant prior sexual intercourse , otherwise , allow . 1. use exogenous estrogen within precede four week 2. current vaginal infection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>estrogen receptor positive breast cancer</keyword>
	<keyword>breast cancer</keyword>
</DOC>